Assessment of Hearing Screening Combined With Limited and Expanded Genetic Screening for Newborns in Nantong, China.

Importance: Early identification and intervention for newborns with hearing loss (HL) may lead to improved physiological and social-emotional outcomes. The current newborn hearing screening is generally beneficial but improvements can be made. Objective: To assess feasibility and evaluate utility of a modified genetic and hearing screening program for newborn infants. Design, Setting, and Participants: This population-based cohort study used a 4-stage genetic and hearing screening program at 6 local hospitals in Nantong city, China. Participants were newborn infants born between January 2016 and June 2020 from the Han population. Statistical analysis was performed from April 1 to May 1, 2021. Exposures: Limited genetic screening for 15 variants in 4 common HL-associated genes and newborn hearing screening (NHS) were offered concurrently to all newborns. Hearing rescreening and/or diagnostic tests were provided for infants with evidence of HL on NHS or genetic variants on screening. Expanded genetic tests for a broader range of genes were targeted to infants with HL with negative results of limited genetic tests. Main Outcomes and Measures: The detection capability for infants with hearing impairment who passed conventional hearing screening, as well as infants with normal hearing at risk of late-onset HL due to genetic susceptibility. Results: Among a total of 35 930 infants, 32 512 infants completed the follow-up and were included for analysis. Among the infants included in the analysis, all were from the Han population in China and 52.3% (16 988) were male. The modified genetic and hearing screening program revealed 142 cases of HL and 1299 cases of genetic variation. The limited genetic screening helped identify 31 infants who passed newborn hearing screening, reducing time for diagnosis and intervention; 425 infants with normal hearing with pathogenic SLC26A4 variation and 92 infants with MT-RNR1 variation were at risk for enlarged vestibular aqueduct and aminoglycoside-induced ototoxicity respectively, indicating early aversive or preventive management. Conclusions and Relevance: This study found that performing modified genetic and hearing screening in newborns was feasible and provides evidence that the program could identify additional subgroups of infants who need early intervention. These findings suggest an advantage for universal adoption of such a practice.

Monodisperse Al-Doped ZnO/Perovskite Nanocapsule.

We developed monodisperse ZnO nanocapsules and atmospheric N plasma was used to develop a ZnO-organic nanocomposite. To test the seal of the ZnO nanocapsule, the halide perovskite CH3NH3PbBr3 was used as the filler. Al atoms were doped into ZnO nanorods to increase the conductivity of ZnO nanorods. A green emission peak located at 535 nm was observed in the nanocapsules with a 410 nm excitation because of the free-exciton recombination of CH3NH3PbBr3. The Al-doped ZnO (AZO)/CH3NH3PbBr3 nanocapsules was further tested under using a three-electrode photoelectrochemistry cell. AZO/CH3NH3PbBr3 nanocapsule arrays yield an elevated photocurrent of approximately 0.2 mA/cm2 at 1 V versus Ag/AgCl under air mass 1.5 (AM 1.5), almost 1.5 times larger than that of the AZO nanorod arrays. The photo-current stability of AZO/CH3NH3PbBr3 nanocapsule arrays photoelectrode is better than that of AZO nanorod arrays under a repeated on/off light test. This confirmed that the AZO/CH3NH3PbBr3 nanocapsules had been successfully sealed and that the degradation of CH3NH3PbNBr3 was thus dramatically reduced. Our study yields a novel platform for nanoscale optical and optoelectronic devices or for delivery of highly toxic drugs.